Turn ASCO data into business-critical insights. 30 high-prescribing hem/oncs analyze 8-10 Multiple Myeloma abstracts to help you prepare for what’s next. Take the guesswork out of understanding changes in prescribing behavior for elranatamab, talquetamab, teclistamab, cilta-cel, ide-cel, and GC012F among others. Get your 60+ slide report.

Multiple Myeloma Report ASCO 2021

American Society of Clinical Oncology

Virtual Meeting
Jun 4 to Jun 8

Share: